Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
C7 you may be right about options 'vested' but unless the options are 'exercised', there won't be much 'skin in the game' will there ?
It's obviously encouraging IF Directors commit their own cash to the Company, but that said, their personal issues (which we have no right to know about), may interfere or preclude.
I'm off now M8 as dawn breaks - TCOY.
Bermudashorts,
Was CH not awarded share options to be vested at 22p when he began his tenure as CEO??
Chelsea,
Some fair points but it's not a question of CH increasing his holding - he doesn't actually own any Scancell shares at all.
And only on the 3rd February after the interins we were trading on 7.50/8.30 with news of anothe collaboratin and thr granting of the IND by the FDA.
Recent spikes we have risen slowly, ending the days on a new high, that day we rose 16% briefly in early trading, ending up 8% up and have slippedback regularly from there.
We have discussed raisings, possibly around April and I wonder if the IND Approval has brought fears of a raising below our current SP? Both sides made some good points, there was a feeling (historically) we haven" made enough progress there, but as I said an raiing like the last one might bring a 15% dilution, but the shar rose to 9.75 pretty quickly for an 80% profit on the 5p buy in.
So it is an important raise, another opportunity to see us fundew well for our plans at a minimal loss for PIs. Sincerely hoping this next round is something new tat Vulpes can put into place and set us up for the year ahesd where commercial deals for TCR/Glycans and AVIDAMAB can leave us with a strong cash in hand position. and at theend of 2020.
Before my posts were twisted in a distrbing way yesterday, we were diccussing "skin in the game"", it was suggested the Directors could buy shares easily looking at their salaries, and my comment around CHs salary was to say it does not in a year snce his rise mean he has considerable sums available to buy shares, probably preffering to rely on performance options. Torquay Fan as others here know the sacrifices I have made in the last ten years since I had to give up my businesses and I wonder why he objected so deeply to a comment that in my heyday i could amd did earn that,but it doesn"t mean CH has huge funds available for a long term commitment in increasing his holding, and nor takes into account those of us in our own businesseswho at times in their life where their financial commitments are earmarked elsewhere. I feel sure a very good remuneration package awaits on success of those collaborations.
Would look forward to hearing others opinions, and reminding us all a raising is a necessity, and no need to be automatically as a big negative. ATB, enjoy your weekend.
Sorry.............."".Next stop IMHO is that £40m M.Cap around 6p. ATB""..................make that 8/8.5p
Yeah an odd week, which we began at 7/7.50 and closed at 6.40/6.50, with a tick up.
Reflective of the week, not IMHO.
We closed aboyt 11% dowm from Monday and Tuesday and Tuesday was the biggest drop taking into account the 605k sell, which as bobust explaines was probably part of the 695k Buy, for a SIPP deposit. Leavibg those two trades out of the compilation of trades, we traded 2.011m shares this week, of which
Buys were 1.026m
Sells were 985k
So we finished 10% down on the bid and 13% on the Ask although 100k were picked up late at 6.70
So we are at the bottom of the 6.50/8 "range"" but the MMs are now at 6.46 for in excess of 235k shares, and we have in the past few weeks seen a fair few 100k buys up to 7.50, at least around 7p.
So glad we finished the week with the MMs needing/wanting shares,but wondering what made us fall so much early in the week.
I think FWIW we will get a nice blue week, trading around 7p very soon, and next week?? New of a fourth collaboration or an update on SCIB1 sites in Both U.S AND U.K for patients dosed in Q3 will be good news for us. Plus whatever else might come. Reading the conversation this morning with a few, there are real chances of a commercial dealthere too.
Importantly we are at a M/Cap of £30m, it has been £40m of late, and I feel for a company with platforms converging to 3 trials in maybe 12 months and collaboration from Avidamab we are well set to be seen as a very good investment, as Vulpes indeed saw us last July.
Next stop IMHO is that £40m M.Cap around 6p. ATB